American Renal Associates Holdings, Inc. Announces Closing of Initial Public Offering

04/25/2016
Press Release

BEVERLY, Mass. -- American Renal Associates Holdings, Inc. (“ARA”) today announced the closing of its initial public offering of 8,625,000 shares of common stock at an initial public offering price of $22.00 per share. The total number of shares sold in the offering includes 1,125,000 shares of common stock sold upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by ARA. ARA’s common stock began trading on the New York Stock Exchange under the ticker symbol “ARA” on April 21, 2016.

BofA Merrill Lynch, Barclays and Goldman, Sachs & Co. served as lead joint book-running managers and as representatives of the underwriters for the offering. Wells Fargo Securities, LLC and SunTrust Robinson Humphrey acted as joint book-running managers. Leerink Partners acted as co-manager dg.prospectus_requests@baml.com, Barclays Capital Inc., c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, email: Barclaysprospectus@broadridge.com or Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, email: prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About American Renal Associates
As of December 31, 2015, American Renal Associates Holdings, Inc. (ARA) operated 192 dialysis clinic locations in 24 states and the District of Columbia, treating over 13,000 patients with end stage renal disease. ARA operates exclusively through a physician joint venture model, in which it partners with 347 local nephrologists to develop, own and operate dialysis clinics.

Contact
Darren Lehrich, SVP Strategy & Investor Relations
978-922-3080 x134
dlehrich@americanrenal.com